Is Symbiox Investme overvalued or undervalued?

As of 27 June 2025, the valuation grade for Symbiox Investme has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 8.67, a price to book value of 0.27, and a PEG ratio of 0.05, indicating a low valuation relative to its growth potential.
In comparison with peers, Symbiox's PE ratio is significantly lower than that of Life Insurance at 12.53 and I R F C at 28.13, both of which are also rated fair. Notably, the EV to EBITDA ratio for Symbiox is -2.44, which stands out against the industry norms. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -48.89% compared to the Sensex's 7.58%, the current valuation suggests that the stock may present a buying opportunity for investors looking for value in the NBFC sector.